Medical Condition News

RSS

IASIS Healthcare, Aurora announce collaboration

Aurora Health Care and IASIS Healthcare today announced a wide ranging partnership which includes the formation of a development joint venture, Aurora IASIS Health Partners, to pursue healthcare acquisitions, new construction, management of facilities and development of clinical services with an initial focus on new and existing markets in Wisconsin and northern Illinois.

28 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Nearly 7% of urologic MDCT scans for hematuria result in incidental findings

A new study from Rhode Island Hospital reports that nearly seven percent of urologic multi-detector computed tomography (MDCT) scans for hematuria result in incidental findings that may be clinically important for the patient. The study is published in the American Journal of Roentgenology.

28 Aug 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Reducing TV viewing may effectively prevent excess weight gain among adolescents

Reducing television viewing may be an effective strategy to prevent excess weight gain among adolescents, according to a new study released in the September/October 2012 issue of the Journal of Nutrition Education and Behavior.

28 Aug 2012

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

28 Aug 2012

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.

28 Aug 2012

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

Successive, vigorous bouts of leg compressions following a stroke appear to trigger natural protective mechanisms that reduce damage, researchers report.

28 Aug 2012

America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies

America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies.

28 Aug 2012

Short sleep duration linked to more aggressive breast cancers

Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center's Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University.

28 Aug 2012

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Neuralstem, Inc. announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), with the eighteenth patient treated.

28 Aug 2012

Blockade Medical's Barricade Coil System successfully treats patients with aneurysms

Blockade Medical announced today the first patients have been treated with the Barricade Coil System. Patients treated with the Barricade Coil System presented with diverse cerebral aneurysms.

27 Aug 2012

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Diaverum, one of the world's leading renal care providers, is planning to give more patients the possibility to be treated with peritoneal dialysis to increase their quality of life.

27 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Academic Urology signs new contract with Independence Blue Cross

Academic Urology, the largest urology specialty medical group in Pennsylvania, announced today that it has signed a new contract with Independence Blue Cross (IBC).

27 Aug 2012

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.

27 Aug 2012

Healthy foods consumed more often by the wealthy than poor

Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Medical Condition News

IASIS Healthcare, Aurora announce collaboration

Novartis receives EC approval for Jakavi to treat myelofibrosis

Nearly 7% of urologic MDCT scans for hematuria result in incidental findings

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Reducing TV viewing may effectively prevent excess weight gain among adolescents

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies

Short sleep duration linked to more aggressive breast cancers

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Blockade Medical's Barricade Coil System successfully treats patients with aneurysms

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Insulin glargine retards progression of atherosclerosis in high-risk people

Academic Urology signs new contract with Independence Blue Cross

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Healthy foods consumed more often by the wealthy than poor

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News